IZMIR, TURKEY (UroToday.com) - Provenge has been shown to improve the survival of men with castrate resistant prostate cancer (CRPC).
Your session will expire in 8 hours requiring you to log in each day to view content.
Browse Categories
IPF 2009 - Treatment of metastatic prostate cancer: New strategies - Session Highlights
Your session will expire in 8 hours requiring you to log in each day to view content.